NEW YORK (GenomeWeb News) — The US Food and Drug Administration has determined that Cepheid’s methicillin-resistant Staphylococcus aureus test is of “moderate complexity” under its Clinical Laboratory Improvement Amendments guidelines, the company said today.
 
Cepheid said that the categorization will enable the Xpert MRSA test to be used both within and outside traditional hospital labs.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.